The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Asthma is a common prevalent chronic respiratory illness that affects millions of people all over the world in every age group. Asthma is defined as inflamed and constricted airways, causing repeated ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. This week’s issue of the prestigious medical journal the Lancet is ...

Shares of Jasper Therapeutics jumped after the company disclosed what it called positive preliminary clinical data from an early-stage trial of its drug to treat asthma. The stock climbed 34%, to ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...